First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.
Microbiol Spectr
; 12(6): e0410523, 2024 Jun 04.
Article
en En
| MEDLINE
| ID: mdl-38700337
ABSTRACT
Resistance to ceftazidime-avibactam (CZA) due to Klebsiella pneumoniae carbapenemase (KPC) variants is increasing worldwide. We characterized two CZA-resistant clinical Klebsiella pneumoniae strains by antimicrobial susceptibility test, conjugation assays, and WGS. Isolates belonged to ST258 and ST45, and produced a KPC-31 and a novel variant KPC-197, respectively. The novel KPC variant presents a deletion of two amino acids on the Ω-loop (del_168-169_EL) and an insertion of two amino acids in position 274 (Ins_274_DS). Continued surveillance of KPC variants conferring CZA resistance in Colombia is warranted. IMPORTANCE Latin America and the Caribbean is an endemic region for carbapenemases. Increasingly high rates of Klebsiella pneumoniae carbapenemase (KPC) have established ceftazidime-avibactam (CZA) as an essential antimicrobial for the treatment of infections due to MDR Gram-negative pathogens. Although other countries in the region have reported the emergence of CZA-resistant KPC variants, this is the first description of such enzymes in Colombia. This finding warrants active surveillance, as dissemination of these variants could have devastating public health consequences.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Proteínas Bacterianas
/
Beta-Lactamasas
/
Infecciones por Klebsiella
/
Pruebas de Sensibilidad Microbiana
/
Ceftazidima
/
Farmacorresistencia Bacteriana Múltiple
/
Combinación de Medicamentos
/
Compuestos de Azabiciclo
/
Klebsiella pneumoniae
/
Antibacterianos
Límite:
Humans
País como asunto:
America do sul
/
Colombia
Idioma:
En
Año:
2024
Tipo del documento:
Article